Cantor Fitzgerald raised the firm’s price target on Zevra Therapeutics (ZVRA) to $29 from $25 and keeps an Overweight rating on the shares. Miplyffa stands a good chance of approval in the EU, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics initiated with a Buy at H.C. Wainwright
- Zevra Therapeutics Elects New Directors at Annual Meeting
- Zevra announces 3 proxy advisory firms recommended vote ‘FOR’ Dixon, Favorito
- Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
- Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating